April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
ApexOnco Front Page
Recent articles
Antibody-drug conjugates hitting this target abound.
The company scraps nemvaleukin after the latest failure, of Artistry-6.
TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.
TLX101 follows Ipax-1 with an apparent success in an academic trial.
J&J's new anti-ENPP3 ADC appears – and then disappears – from a clinical study listing.
Meanwhile, Akeso challenges Moderna and BioNTech with an mRNA neoantigen play.
The group could soon provide clarity on CTX112’s regulatory path.
